Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITDAEPS (Basic)EPS (Weighted Average and Diluted)Interest & Investment IncomeInterest ExpensesInterest ExpensesNon Operating IncomeOperating ExpensesOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Achieve Life Sciences (ACHV) EBITDA (2016 - 2026)

Achieve Life Sciences (ACHV) has disclosed EBITDA for 15 consecutive years, with -$10.2 million as the latest value for Q1 2026.

  • Quarterly EBITDA rose 20.82% to -$10.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$50.2 million through Mar 2026, down 24.69% year-over-year, with the annual reading at -$16.4 million for FY2019, 29.23% down from the prior year.
  • EBITDA for Q1 2026 was -$10.2 million at Achieve Life Sciences, up from -$14.4 million in the prior quarter.
  • The five-year high for EBITDA was -$6.5 million in Q1 2024, with the low at -$14.4 million in Q3 2025.
  • Average EBITDA over 4 years is -$10.3 million, with a median of -$10.2 million recorded in 2026.
  • The sharpest move saw EBITDA crashed 97.91% in 2025, then grew 20.82% in 2026.
  • Achieve Life Sciences' EBITDA stood at -$7.1 million in 2023, then crashed by 74.87% to -$12.4 million in 2024, then decreased by 16.13% to -$14.4 million in 2025, then increased by 29.5% to -$10.2 million in 2026.
  • Per Business Quant, the three most recent readings for ACHV's EBITDA are -$10.2 million (Q1 2026), -$14.4 million (Q3 2025), and -$12.7 million (Q2 2025).